AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
4,925.00
-10.00 (-0.20%)
At close: 5:11PM GMT
Stock chart is not supported by your current browser
Previous Close4,935.00
Open4,920.50
Bid4,850.00 x 6100
Ask4,980.00 x 13000
Day's Range4,898.00 - 5,011.91
52 Week Range4,136.50 - 5,520.00
Volume2,169,972
Avg. Volume2,270,586
Market Cap62.35B
Beta0.63
PE Ratio (TTM)16.15
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.79 (4.51%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool2 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Reuters2 days ago

    Merck raises stakes in lung cancer as rivals close in

    Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.

  • Capital Cube6 days ago

    ETFs with exposure to AstraZeneca Plc : December 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AstraZeneca Plc Here are 5 ETFs with the largest exposure to AZN-GB. Comparing the performance and risk of AstraZeneca Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Reuters6 days ago

    Companies prepare for disorderly Brexit as talks stall

    Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. Senior executives in the financial services sector, which accounts for about 12 percent of the economy, told Reuters May's efforts to secure a transition deal had come too late and they had no choice but to start restructuring.

  • Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down
    Investor's Business Daily7 days ago

    Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down

    Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.

  • GSK, other drugmakers bet on post-Brexit UK science
    Reuters7 days ago

    GSK, other drugmakers bet on post-Brexit UK science

    Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

  • A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster
    Bloomberg8 days ago

    A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster

    Taking Seroquel with methadone can be fatal. Did the drugmaker’s warnings fall short?

  • AstraZeneca Plc :AZN-GB: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
    Capital Cube8 days ago

    AstraZeneca Plc :AZN-GB: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017

    Categories: Yahoo FinanceGet free summary analysis AstraZeneca Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of AstraZeneca Plc – GlaxoSmithKline plc, Shire PLC, Abbott Laboratories, Novo Nordisk A/S Class B, Eli Lilly and Company and Pfizer Inc. (GSK-GB, SHP-GB, ABT-CH, NOVO.B-DK, LLY-CH and PFE-SE) that ... Read more (Read more...)

  • Barrons.com8 days ago

    [$$] AstraZeneca Sells $10.7 Million in Albireo Stock

    AstraZeneca has halved its investment in Albireo Pharma. A subsidiary of AstraZeneca (ticker: AZN), AstraZeneca AB, sold 500,000 Albireo (ALBO) shares for $10.7 million, or $21.40 each on Dec. 1. AstraZeneca ...

  • FDA approves diabetes drug that also helps with weight loss
    Associated Press8 days ago

    FDA approves diabetes drug that also helps with weight loss

    TRENTON, N.J. (AP) — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.

  • Barrons.com8 days ago

    [$$] AstraZeneca Sells $6.6M in G1 Therapeutics Stock

    G1 Therapeutics, a clinical-stage oncology company, announced a collaboration with AstraZeneca Nov. 28. The pact will evaluate AstraZeneca’s (AZN) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in combination with G1’s (GTHX) oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The press release didn’t mention that AstraZeneca, through its MedImmune Ventures subsidiary, is a significant shareholder in G1 nor that MedImmune Ventures has been selling G1 shares.

  • AstraZeneca's COPD Drug Succeeds in Label Expansion Study
    Zacks8 days ago

    AstraZeneca's COPD Drug Succeeds in Label Expansion Study

    AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

  • 50,000 New Drug Tests Among Brexit Worries for Pharma Companies
    Bloomberg10 days ago

    50,000 New Drug Tests Among Brexit Worries for Pharma Companies

    Global drugmakers from Johnson & Johnson to AstraZeneca Plc warned that potential trade and regulatory hurdles may burden them with a host of additional costs after Britain leaves the European Union.

  • Market Realist12 days ago

    Gauging Novartis’s Valuation This November

    Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.

  • Benzinga12 days ago

    FDA Decisions In November: The Month In Review

    Rounding out a month marked mostly by positive decisions, FDA announced its approval late for Sublocade, a once-monthly injectable buprenorphine product for the treatment of opioid addiction. U.K.-listed ...

  • What Does AstraZeneca PLC’s (LSE:AZN) Share Price Indicate?
    Simply Wall St.13 days ago

    What Does AstraZeneca PLC’s (LSE:AZN) Share Price Indicate?

    AstraZeneca PLC (LSE:AZN) saw significant share price volatility over the past couple of months on the LSE, rising to the highs of £51.8 and falling to the lows of £45.74.Read More...

  • AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
    Zacks14 days ago

    AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

    AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

  • Market Realist15 days ago

    Nektar Therapeutics Raised Its Revenue Guidance for 2017

    After the collaboration with Eli Lilly for investigational drug NKTR-358, Nektar Therapeutics (NKTR) increased its 2017 revenue projections to $250 million–$255 million.

  • American City Business Journals15 days ago

    RTP company lands work with AstraZeneca

    Research Triangle Park-based G1 Therapeutics (GTHX) – which raised more than $108 million in its initial public offering earlier this year – has landed work with global biopharmaceutical behemoth AstraZeneca. According to G1, it “will sponsor and conduct the Phase 1b/2 study in collaboration with AstraZeneca.” However, financial terms of the collaboration and resulting study – expected to commence in the first quarter of next year – are not being disclosed.

  • AstraZeneca Files for Label Expansion of Tagrisso in Japan
    Zacks15 days ago

    AstraZeneca Files for Label Expansion of Tagrisso in Japan

    AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

  • American City Business Journals16 days ago

    AstraZeneca forms joint venture in China

    AstraZeneca said Monday it has formed a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to create a stand-alone company in China to discover, develop and commercialize potential new medicines. The new company, Dizal Pharmaceutical, will be equally owned by AstraZeneca and FIIF, which is managed by the private equity management firm SDIC Fund Management Co. “AstraZeneca has a long-standing and strong commitment to China, which we are reinforcing today with this ground-breaking joint venture,” said Pascal Soriot, CEO of AstraZeneca.

  • AstraZeneca steps up China push with new drug joint venture
    Reuters17 days ago

    AstraZeneca steps up China push with new drug joint venture

    Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said on Monday. By getting into bed with a local player, AstraZeneca aims to ride a wave of regulatory reform in China's pharmaceuticals sector and get new drugs to market more quickly.

  • Reuters17 days ago

    AstraZeneca steps up China push with new drug joint venture

    Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said on Monday. By getting into bed with a local player, AstraZeneca aims to ride a wave of regulatory reform in China's pharmaceuticals sector and get new drugs to market more quickly.

  • 3 Companies Competing to Gain Lead in Ovarian Cancer Market
    Zacks19 days ago

    3 Companies Competing to Gain Lead in Ovarian Cancer Market

    Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

  • Top 10 Largest Pharmaceutical Companies By Revenue in 2017
    Insider Monkey20 days ago

    Top 10 Largest Pharmaceutical Companies By Revenue in 2017

    The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]